Lixte Biotechnology Holdings, Inc. Warrants (LIXTW)

• Market cap: $77.9K
• 1 day: 0.00%
• 5 days: -12.41%
• 1 month: 63.21%
• 3 months: -30.38%
• 6 months: 24.01%
• Year to date: 23.57%
• 1 year: -61.56%
• 5 years: -96.88%
• 10 years: -96.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Employees: 4

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding

Funds holding: 2 [Q4 2024] → 3 (+1) [Q1 2025]

14% more capital invested

Capital invested by funds: $1.44K [Q4 2024] → $1.65K (+$205) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.05% less ownership

Funds ownership: 2.22% [Q4 2024] → 2.17% (-0.05%) [Q1 2025]